2023 Partners

Official 2023 Partners - 6th TPD Summit

We are proud to have been the definitive event of the year, uniting large pharma, innovative biotech, and world-renowned academics to discuss the full breadth of protein degrader drug development. You can learn more about our official partners for 2023 below.

If you would like to learn more about our bespoke sponsorship opportunities for next year, get in touch today.

Promega

Lead Partner

See More:

Promega is committed to excellence in technologies and compound profiling services to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRIPSR HiBiT content covers hundreds of pre-built targets. Novel software analysis tools allow for the determination of target protein degradation rates, DC50 potency values, recovery profiles and more.

www.promega.com

Bruker

Workshop Hosting Partner

See More:

Cell Signalling Technology

Hosting Partner

See More:

NJ Bio, Inc.

Program Partner

See More:

NJ Biopharmaceuticals is a quality CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include multistep organic synthesis, medicinal chemistry, bioconjugation, antibody-drug conjugates, and flow chemistry. The company is headquartered in Princeton, NJ, with an additional chemistry facility in Bristol, PA.

www.njbio.com

NEOsphere Biotechnologies

Program Partner

See More:

Operating at the forefront of innovation within Munich’s biotech hub, we use cutting-edge mass spectrometry technologies to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Our integrated target discovery engine accesses this unprecedented molecular landscape to connect innovative degrader chemistries with the previously undruggable proteome.

www.neospherebiotechnologies.com

HitGen Inc.

Program Partner

See More:

HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen’s DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds.

www.hitgen.com

SCIEX

Program Partner

See More:

SCIEX offers mass spec and capillary electrophoresis solutions for scientists seeking innovative and reliable analytical experimentation, from routine testing to complex workflows. Our solutions capture the best data, integrate cross-omics results, and deliver relevant insights to enable discovery of key genes, proteins, lipids, and metabolites. With solutions designed by scientists, we empower our customers to transform their workflows and gain more reliable information for their research.

www.sciex.com

X-CHEM

Program Partner

See More:

Syngene International

Program Partner

See More:

Catalent Pharma Solutions

Program Partner

See More:

Bio-Techne

Innovation Partner

See More:

Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

www.bio-techne.com

See More:

LifeSensors, Inc. is a biotechnology company leading the development of innovative research tools and services for the ubiquitin and ubiquitin-like protein pathways. Our unique capability is provide researchers with solutions along every aspect of the ubiquitin proteasome pathway – E3 ligases, DUB enzymes/assays/substrates, ubiquitin chains and mutants, inhibitors, ubiquitin isolation and detection reagents and kits to measure substrate ubiquitylation.

www.lifesensors.com

Pelago Bioscience

Innovation Partner

See More:

Refeyn

Innovation Partner

See More:

Refeyn, the pioneer of mass photometry, is delivering a disruptive new generation of analytical instruments that let you weigh individual molecules with light. Mass photometry offers new possibilities to characterise the function, structural composition and dynamics of biomolecules. Refeyn instruments measure the mass of individual molecules directly in solution, rapidly, and simply, revealing the true behaviour of molecules in near-native environments, providing scientists with key information about their mass distribution.

www.refeyn.com

Biotheryx

Industry Partner

See More:

Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform

www.biotheryx.com

C4 Therapeutics

Industry Partner

See More:

C4 Therapeutics (C4T) is a clinical-stage biotechnology company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. We are leveraging our TORPEDO® platform to rapidly and efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.

www.c4therapeutics.com

Orionis Biosciences

Industry Partner

See More:

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

www.orionisbio.com

Aragen

Exhibition Partner

See More:

We have more than 20 years of experience providing a range of contract research, development and manufacturing services across the drug development continuum, with a focus on early-stage discovery and development of new molecular entities (NMEs). Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

www.aragen.com

Inomics

Exhibition Partner

See More:

Inomics now offers a complete line of mass spectrometry services to accelerate your TPD research and drug development needs. Our laboratory in San Jose, California is staffed by experienced scientists, equipped with cutting-edge LC-MS/MS instrumentation and advanced bioinformatics capabilities. Our state-of-the-art mythology can help simplify the challenge of proteomic analysis, metabolomics analysis and biologics characterization. We provide services for biomarker discovery, drug target deconvolution, mechanism of action, candidate ligand screening, and comprehensive characterization of biologics.

www.inomics.com

Biognosys

Exhibition Partner

See More:

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species.

www.biognosys.com

Charnwood Discovery

Exhibition Partner

See More:

Charnwood Discovery is a leading provider of drug discovery services, from standalone customized solutions through to fully integrated programs that enhance the experience and success of complex drug discovery.

Our collaborative and efficient approach ensures we add value across the drug discovery pipeline from target validation through to pre-clinical candidates. Whether you need a standalone or fully integrated solution our multidisciplinary teams provide innovation and excellence at every stage.

www.charnwooddiscovery.com

Nanoimaging Services

Exhibition Partner

See More:

Visualizing biomolecular structures through cryo-EM studies can provide insight into multiple stages of the drug development process, from target identification through formulation and manufacturing. As the industry leader with the longest history in cryo-EM, and with more cryo-EM scientists and TEM microscopes than any provider in North America, NIS is focused on three areas of cutting-edge science: target enablement, characterization, and small molecule microED.

www.nanoimaginingservices.com

Nanome

Exhibiton Partner

See More:

Nanome is the ultimate interface for scientific discovery, starting with molecular data. Top R&D labs conduct cutting-edge research and make billion-dollar decisions in Nanome. But, Nanome isn’t just for experts, it’s also used by students and amateur scientists studying chemistry and biology. Anyone can build 3D molecules or simulate an entire protein made of hundreds of atoms, all in one collaborative environment.

www.nanone.ai

Fidabio

Exhibiton Partner

See More:

Fidabio assist you realizing the full potential of your complex biology beyond current technologies. We offer a completely new way to quantify and characterize complex biology in native conditions. Flow Induced Dispersion Analysis (FIDA) is a revolutionary “1^st principle” technology for in solution, quantification and characterization of proteins and particles with diameter from 0.5 to 1000 nm in diameter, including complex interactions, stoichiometry, oligomeric states etc.

www.fidabio.com

PREOMICS

Exhibiton Partner

See More:

Setting the Standard for Protein Analysis.

PreOmics empowers our clients in life sciences to establish biological knowledge through efficient, reliable solutions and workflows that set the standard for protein analysis.

Our team spirit, energy, and commitment empower us to be both creative and quality focused – A trusted partner with deeply rooted scientific experience.

We envisage a future with revolutionary proteomic discovery processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable nutrition, and provide diagnoses that enhance lives and society.

www.preomics.com

Bioduro-Sundia

Exhibiton Partner

See More:

BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China and has 10 global sites across 7 cities.

www.biodura-sundia.com

Collaborative Drug Discovery

Exhibiton Partner

See More:

Virtual Discovery

Exhibiton Partner

See More:

Virtual Discovery leverages cutting-edge technology initially developed in the Harvard Wagner Lab to revolutionize early-stage drug discovery. Our VirtualFlow 2.0 platform conducts expansive in silico screens, evaluating 69+ billion drug-like molecules from Enamine's REAL library in a convenient "ready-to-dock" format. Through our 18-dimensional exploration of the Enamine library (with each dimension representing a distinct molecular property), we excel in hit identification and lead optimization to achieve superior binding affinity. Our VirtualFlow 2.0 platform harnesses advanced deep learning and GPU-based docking methods, ensuring enhanced speed and quality. This empowers us to efficiently screen diverse ligands like peptides and target receptors, including DNA and RNA.

www.virtualdiscovery.net

WuXi AppTec

Exhibition Partner

See More:

WuXi AppTec provides a full spectrum of services to support research focused on targeted protein degradation. Our discovery platform allows for in-depth biological and biophysical characterization of bifunctional molecules. We offer proximity assays to measure ternary complex formation, target protein ubiquitination and degradation assays, and high-resolution X-ray crystallography of binary and ternary complexes. Our platform also includes extensive chemistry services, such as custom synthesis, scale-up, and purification of new linkers and E3 ligase ligands.

www.wuxiapptec.com

Biortus

Exhibition Partner

See More:

Biortus is a structure-based drug discovery CRO with a mature protein focused lead generation platform including modular services in protein production, assay development, fragment screening, and structure determination in microED, CryoEM, and X-ray crystallography. We’ve solved structures of some ternary degradation complexes including VHL and CRBN based PROTACs. Our newest Boston site is available for 2-way sample shipment and serves as the headquarters for our off-the-shelf Protein Catalog which includes DUBS, E3 ligases, and more.

www.en.wuxibiortus.com

Inoviv

Exhibition Partner

See More:

At Inoviv, we support clinical proteomics by developing relevant LC-MS biomarker assays with exceptional throughput and selectivity, providing actionable proteomics insights that accelerate drug development. Our targeted custom and off-the-shelf LC MS panels are expertly curated for monitoring degradation products, treatment efficacy, quantification of different proteoforms and improved patient stratification and selection in a wide range of tissue and biofluid samples across neurodegeneration, oncology, fibrosis, cardiovascular disease and more.

www.inoviv.com

Seran Bioscience

Exhibition Partner

See More:

Beacon

Event Partner

See More:

Targeted Protein Degradation Summit - Partner With Us

2023 Partners

Official 2023 Partners - 6th TPD Summit

Promega

Bruker

Cell Signalling Technology

NJ Bio, Inc.

NEOsphere Biotechnologies

HitGen Inc.

SCIEX

X-CHEM

Syngene International

Catalent Pharma Solutions

Bio-Techne

Pelago Bioscience

Refeyn

Biotheryx

C4 Therapeutics

Orionis Biosciences

Aragen

Inomics

Biognosys

Charnwood Discovery

Nanoimaging Services

Nanome

Fidabio

PREOMICS

Bioduro-Sundia

Collaborative Drug Discovery

Virtual Discovery

WuXi AppTec

Biortus

Inoviv

Seran Bioscience

Beacon

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH